Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 799 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia June 5, 2018 New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free September 19, 2019 Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ November 29, 2021 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 Load more HOT NEWS Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer...
